【AI详解】Systems vaccinology of the BNT162b2 mRNA vaccine in humans.

文献信息

一句话小结

本研究通过系统疫苗学方法分析辉瑞-BioNTech mRNA疫苗接种后健康志愿者的免疫反应，发现疫苗能有效产生针对SARS-CoV-2的中和抗体，并在加强针接种后显著增强先天免疫反应。这些发现为理解mRNA疫苗的免疫机制提供了重要数据，有助于优化疫苗策略以应对新变种病毒。

在麦伴科研 (maltsci.com) 搜索更多文献

mRNA疫苗 · 免疫反应 · 中和抗体 · 系统疫苗学 · T细胞

摘要

两种mRNA疫苗在SARS-CoV-2出现不到一年时间内获得紧急使用授权，标志着疫苗学的一个重要里程碑。然而，mRNA疫苗如何刺激免疫系统以引发保护性免疫反应仍然未知。在此，我们采用系统疫苗学的方法，全面分析了56名接种辉瑞-BioNTech mRNA疫苗（BNT162b2）的健康志愿者的先天和适应性免疫反应。疫苗接种导致对野生型SARS-CoV-2（源自2019-nCOV/USA_WA1/2020）产生了强效的中和抗体，并在较小程度上对B.1.351株也产生了反应，同时在第二剂接种后，抗原特异性的多功能CD4和CD8 T细胞显著增加。加强针接种相比初次接种刺激了明显增强的先天免疫反应，体现在以下几个方面：（1）CD14+CD16+炎症单核细胞的频率更高；（2）血浆中IFNγ的浓度更高；（3）先天抗病毒免疫的转录特征。与这些观察结果一致的是，我们的单细胞转录组分析显示，在二次免疫接种后，富含干扰素反应转录因子的髓系细胞簇的频率约增加了100倍，而AP-1转录因子的频率则降低。最后，我们识别了与CD8 T细胞和中和抗体反应相关的不同先天通路，并显示单核细胞相关特征与对B.1.351变种的中和抗体反应相关。总体而言，这些数据为mRNA疫苗接种引发的免疫反应提供了见解，并证明其能够激活先天免疫系统，以便在加强免疫后产生更强效的反应。

英文摘要

The emergency use authorization of two mRNA vaccines in less than a year from the emergence of SARS-CoV-2 represents a landmark in vaccinology1,2. Yet, how mRNA vaccines stimulate the immune system to elicit protective immune responses is unknown. Here we used a systems vaccinology approach to comprehensively profile the innate and adaptive immune responses of 56 healthy volunteers who were vaccinated with the Pfizer-BioNTech mRNA vaccine (BNT162b2). Vaccination resulted in the robust production of neutralizing antibodies against the wild-type SARS-CoV-2 (derived from 2019-nCOV/USA_WA1/2020) and, to a lesser extent, the B.1.351 strain, as well as significant increases in antigen-specific polyfunctional CD4 and CD8 T cells after the second dose. Booster vaccination stimulated a notably enhanced innate immune response as compared to primary vaccination, evidenced by (1) a greater frequency of CD14+CD16+ inflammatory monocytes; (2) a higher concentration of plasma IFNγ; and (3) a transcriptional signature of innate antiviral immunity. Consistent with these observations, our single-cell transcriptomics analysis demonstrated an approximately 100-fold increase in the frequency of a myeloid cell cluster enriched in interferon-response transcription factors and reduced in AP-1 transcription factors, after secondary immunization. Finally, we identified distinct innate pathways associated with CD8 T cell and neutralizing antibody responses, and show that a monocyte-related signature correlates with the neutralizing antibody response against the B.1.351 variant. Collectively, these data provide insights into the immune responses induced by mRNA vaccination and demonstrate its capacity to prime the innate immune system to mount a more potent response after booster immunization.

麦伴智能科研服务

主要研究问题

1. BNT162b2疫苗在不同人群中的免疫反应是否存在显著差异？
2. 采用系统疫苗学方法时，如何评估疫苗对适应性免疫的影响？
3. 在BNT162b2疫苗接种后，抗体和T细胞反应的长期维持情况如何？
4. mRNA疫苗的初次接种与加强接种在免疫机制上有何不同？
5. 未来的mRNA疫苗研究中，是否会考虑针对新变种的特异性免疫反应？

核心洞察

研究背景和目的

本研究旨在通过系统疫苗学的方法，全面分析BNT162b2 mRNA疫苗在56名健康志愿者中的免疫反应，以揭示该疫苗如何刺激免疫系统并产生保护性免疫反应。尽管BNT162b2在预防严重COVID-19方面表现出95%的有效性，但其对先天免疫反应的影响尚不明确。

主要方法/材料/实验设计

研究采用了系统免疫学的方法，涉及多个实验步骤和技术，包括：

1. 研究设计：本研究为观察性研究，参与者接种两剂BNT162b2疫苗，研究其免疫反应。
2. 入排招募标准：纳入56名健康志愿者，所有参与者均为成年，未有严重疾病史。
3. 分组与随机化方式：所有参与者均接受相同的疫苗接种方案，未进行随机分组。
4. 干预措施：参与者接种两剂BNT162b2疫苗，间隔21天。
5. 主要与次要结局指标：
   • 主要结局：中和抗体的产生及T细胞反应。
   • 次要结局：先天免疫细胞的变化及细胞因子的浓度。
6. 统计分析方法：采用Wilcoxon配对秩和检验和Spearman相关性分析来评估免疫反应的显著性。

关键结果和发现

1. 抗体和T细胞反应：

   • 所有参与者在接种后均产生了结合抗体和中和抗体，第二剂接种后抗体水平显著提高。
   • 接种后7天，检测到针对SARS-CoV-2的特异性CD4和CD8 T细胞反应。

2. 先天免疫反应：

   • 第二剂接种后，CD14+CD16+炎性单核细胞的频率显著增加，IFNγ的浓度也显著提高。
   • 转录组分析显示，在第二次免疫后，干扰素反应转录因子的表达增加。

3. 单细胞转录组分析：

   • 在第二次接种后，发现了一种新的单核细胞群体（C8），其表达干扰素刺激基因的能力显著增强。

4. 年龄与免疫反应的关系：

   • 研究发现，年龄与中和抗体反应呈负相关，年轻参与者的免疫反应更为强烈。

主要结论/意义/创新性

本研究提供了对BNT162b2疫苗诱导的免疫反应的深刻见解，尤其是对先天免疫反应的首次系统分析。结果表明，mRNA疫苗不仅能有效激活适应性免疫，还能显著增强先天免疫反应，尤其是在加强免疫后。这些发现为理解mRNA疫苗的免疫机制提供了重要的基础，并可能为未来疫苗设计和优化提供参考。

研究局限性和未来方向

本研究的局限性包括样本量较小和缺乏长期跟踪数据。未来的研究应扩大样本规模，探讨不同人群（如老年人和免疫抑制者）的反应，并研究疫苗对新冠病毒变异株的免疫保护效果。此外，进一步研究C8单核细胞的功能和其在疫苗应答中的作用将是一个重要的研究方向。

参考文献

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. - Fernando P Polack;Stephen J Thomas;Nicholas Kitchin;Judith Absalon;Alejandra Gurtman;Stephen Lockhart;John L Perez;Gonzalo Pérez Marc;Edson D Moreira;Cristiano Zerbini;Ruth Bailey;Kena A Swanson;Satrajit Roychoudhury;Kenneth Koury;Ping Li;Warren V Kalina;David Cooper;Robert W Frenck;Laura L Hammitt;Özlem Türeci;Haylene Nell;Axel Schaefer;Serhat Ünal;Dina B Tresnan;Susan Mather;Philip R Dormitzer;Uğur Şahin;Kathrin U Jansen;William C Gruber; - The New England journal of medicine (2020)
2. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. - Mark J Mulligan;Kirsten E Lyke;Nicholas Kitchin;Judith Absalon;Alejandra Gurtman;Stephen Lockhart;Kathleen Neuzil;Vanessa Raabe;Ruth Bailey;Kena A Swanson;Ping Li;Kenneth Koury;Warren Kalina;David Cooper;Camila Fontes-Garfias;Pei-Yong Shi;Özlem Türeci;Kristin R Tompkins;Edward E Walsh;Robert Frenck;Ann R Falsey;Philip R Dormitzer;William C Gruber;Uğur Şahin;Kathrin U Jansen - Nature (2020)
3. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. - Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler;Lena M Kranz;Mathias Vormehr;Alina Baum;Kristen Pascal;Jasmin Quandt;Daniel Maurus;Sebastian Brachtendorf;Verena Lörks;Julian Sikorski;Rolf Hilker;Dirk Becker;Ann-Kathrin Eller;Jan Grützner;Carsten Boesler;Corinna Rosenbaum;Marie-Cristine Kühnle;Ulrich Luxemburger;Alexandra Kemmer-Brück;David Langer;Martin Bexon;Stefanie Bolte;Katalin Karikó;Tania Palanche;Boris Fischer;Armin Schultz;Pei-Yong Shi;Camila Fontes-Garfias;John L Perez;Kena A Swanson;Jakob Loschko;Ingrid L Scully;Mark Cutler;Warren Kalina;Christos A Kyratsous;David Cooper;Philip R Dormitzer;Kathrin U Jansen;Özlem Türeci - Nature (2020)
4. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. - Prabhu S Arunachalam;Florian Wimmers;Chris Ka Pun Mok;Ranawaka A P M Perera;Madeleine Scott;Thomas Hagan;Natalia Sigal;Yupeng Feng;Laurel Bristow;Owen Tak-Yin Tsang;Dhananjay Wagh;John Coller;Kathryn L Pellegrini;Dmitri Kazmin;Ghina Alaaeddine;Wai Shing Leung;Jacky Man Chun Chan;Thomas Shiu Hong Chik;Chris Yau Chung Choi;Christopher Huerta;Michele Paine McCullough;Huibin Lv;Evan Anderson;Srilatha Edupuganti;Amit A Upadhyay;Steve E Bosinger;Holden Terry Maecker;Purvesh Khatri;Nadine Rouphael;Malik Peiris;Bali Pulendran - Science (New York, N.Y.) (2020)
5. Systems biology of vaccination for seasonal influenza in humans. - Helder I Nakaya;Jens Wrammert;Eva K Lee;Luigi Racioppi;Stephanie Marie-Kunze;W Nicholas Haining;Anthony R Means;Sudhir P Kasturi;Nooruddin Khan;Gui-Mei Li;Megan McCausland;Vibhu Kanchan;Kenneth E Kokko;Shuzhao Li;Rivka Elbein;Aneesh K Mehta;Alan Aderem;Kanta Subbarao;Rafi Ahmed;Bali Pulendran - Nature immunology (2011)
6. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. - Troy D Querec;Rama S Akondy;Eva K Lee;Weiping Cao;Helder I Nakaya;Dirk Teuwen;Ali Pirani;Kim Gernert;Jiusheng Deng;Bruz Marzolf;Kathleen Kennedy;Haiyan Wu;Soumaya Bennouna;Herold Oluoch;Joseph Miller;Ricardo Z Vencio;Mark Mulligan;Alan Aderem;Rafi Ahmed;Bali Pulendran - Nature immunology (2009)
7. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. - Denis Gaucher;René Therrien;Nadia Kettaf;Bastian R Angermann;Geneviève Boucher;Abdelali Filali-Mouhim;Janice M Moser;Riyaz S Mehta;Donald R Drake;Erika Castro;Rama Akondy;Aline Rinfret;Bader Yassine-Diab;Elias A Said;Younes Chouikh;Mark J Cameron;Robert Clum;David Kelvin;Roland Somogyi;Larry D Greller;Robert S Balderas;Peter Wilkinson;Giuseppe Pantaleo;Jim Tartaglia;Elias K Haddad;Rafick-Pierre Sékaly - The Journal of experimental medicine (2008)
8. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. - John S Tsang;Pamela L Schwartzberg;Yuri Kotliarov;Angelique Biancotto;Zhi Xie;Ronald N Germain;Ena Wang;Matthew J Olnes;Manikandan Narayanan;Hana Golding;Susan Moir;Howard B Dickler;Shira Perl;Foo Cheung; ; - Cell (2014)
9. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. - Nicole Doria-Rose;Mehul S Suthar;Mat Makowski;Sarah O’Connell;Adrian B McDermott;Britta Flach;Julie E Ledgerwood;John R Mascola;Barney S Graham;Bob C Lin;Sijy O’Dell;Stephen D Schmidt;Alicia T Widge;Venkata-Viswanadh Edara;Evan J Anderson;Lilin Lai;Katharine Floyd;Nadine G Rouphael;Veronika Zarnitsyna;Paul C Roberts;Mamodikoe Makhene;Wendy Buchanan;Catherine J Luke;John H Beigel;Lisa A Jackson;Kathleen M Neuzil;Hamilton Bennett;Brett Leav;Jim Albert;Pratap Kunwar; - The New England journal of medicine (2021)
10. Neutralizing Activity of BNT162b2-Elicited Serum. - Yang Liu;Jianying Liu;Hongjie Xia;Xianwen Zhang;Camila R Fontes-Garfias;Kena A Swanson;Hui Cai;Ritu Sarkar;Wei Chen;Mark Cutler;David Cooper;Scott C Weaver;Alexander Muik;Ugur Sahin;Kathrin U Jansen;Xuping Xie;Philip R Dormitzer;Pei-Yong Shi - The New England journal of medicine (2021)

引用本文的文献

1. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. - Wenqiang Sun;Lihong He;He Zhang;Xiaodong Tian;Zhihua Bai;Lei Sun;Limin Yang;Xiaojuan Jia;Yuhai Bi;Tingrong Luo;Gong Cheng;Wenhui Fan;Wenjun Liu;Jing Li - Signal transduction and targeted therapy (2021)
2. Robust immune response to the BNT162b mRNA vaccine in an elderly population vaccinated 15 months after recovery from COVID-19. - Hye Kyung Lee;Ludwig Knabl;Ludwig Knabl;Sebastian Kapferer;Birgit Pateter;Mary Walter;Priscilla A Furth;Lothar Hennighausen - medRxiv : the preprint server for health sciences (2021)
3. Hidden in plain sight: uncovering the role of CREB1 in HIV-1 vaccine-induced immunity. - Helder I Nakaya - Nature immunology (2021)
4. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. - István Vályi-Nagy;Zsolt Matula;Márton Gönczi;Szabolcs Tasnády;Gabriella Bekő;Marienn Réti;Éva Ajzner;Ferenc Uher - GeroScience (2021)
5. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. - Rishi R Goel;Mark M Painter;Sokratis A Apostolidis;Divij Mathew;Wenzhao Meng;Aaron M Rosenfeld;Kendall A Lundgreen;Arnold Reynaldi;David S Khoury;Ajinkya Pattekar;Sigrid Gouma;Leticia Kuri-Cervantes;Philip Hicks;Sarah Dysinger;Amanda Hicks;Harsh Sharma;Sarah Herring;Scott Korte;Amy E Baxter;Derek A Oldridge;Josephine R Giles;Madison E Weirick;Christopher M McAllister;Moses Awofolaju;Nicole Tanenbaum;Elizabeth M Drapeau;Jeanette Dougherty;Sherea Long;Kurt D’Andrea;Jacob T Hamilton;Maura McLaughlin;Justine C Williams;Sharon Adamski;Oliva Kuthuru; ;Ian Frank;Michael R Betts;Laura A Vella;Alba Grifoni;Daniela Weiskopf;Alessandro Sette;Scott E Hensley;Miles P Davenport;Paul Bates;Eline T Luning Prak;Allison R Greenplate;E John Wherry - Science (New York, N.Y.) (2021)
6. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination. - Samy Hakroush;Björn Tampe - Frontiers in immunology (2021)
7. Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. - Rima Hajjo;Dima A Sabbah;Sanaa K Bardaweel;Alexander Tropsha - Vaccines (2021)
8. Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022. - Kevin J Downes;Victoria A Statler;Rachel C Orscheln;Melissa K Cousino;Michael Green;Marian G Michaels;William J Muller;Tanvi S Sharma;Lara A Danziger-Isakov;Monica I Ardura - Journal of the Pediatric Infectious Diseases Society (2022)
9. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. - Hitoshi Kawasuji;Yoshitomo Morinaga;Hideki Tani;Yumiko Saga;Makito Kaneda;Yushi Murai;Akitoshi Ueno;Yuki Miyajima;Yasutaka Fukui;Kentaro Nagaoka;Chikako Ono;Yoshiharu Matsuura;Hideki Niimi;Yoshihiro Yamamoto - Microbiology spectrum (2021)
10. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. - Mohamad-Gabriel Alameh;István Tombácz;Emily Bettini;Katlyn Lederer;Chutamath Sittplangkoon;Joel R Wilmore;Brian T Gaudette;Ousamah Y Soliman;Matthew Pine;Philip Hicks;Tomaz B Manzoni;James J Knox;John L Johnson;Dorottya Laczkó;Hiromi Muramatsu;Benjamin Davis;Wenzhao Meng;Aaron M Rosenfeld;Shirin Strohmeier;Paulo J C Lin;Barbara L Mui;Ying K Tam;Katalin Karikó;Alain Jacquet;Florian Krammer;Paul Bates;Michael P Cancro;Drew Weissman;Eline T Luning Prak;David Allman;Michela Locci;Norbert Pardi - Immunity (2021)

… (290 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研